


PPAR-gamma antagonist imatinib improves insulin sensitivity

January 13 2016



(HealthDay)—Imatinib (Gleevec) blocks CDK5-mediated peroxisome



proliferator-activated receptor γ (PPAR γ) phosphorylation as an antagonist ligand, improving insulin sensitivity and promoting browning of white adipose tissue, according to a study published online Jan. 6 in *Diabetes*.

Sunsil Choi, from the Ulsan National Institute of Science and Technology in South Korea, and colleagues used high throughput phosphorylation screening to describe the mechanism of action of imatinib.

The researchers note that imatinib blocks CDK5-mediated PPAR γ phosphorylation acting as a PPAR γ antagonist ligand. Imatinib improved insulin sensitivity in high fat-fed mice, without causing severe side effects associated with other PPAR γ -targeting drugs. Imatinib was also found to reduce lipogenic and gluconeogenic gene expression in the liver and improved inflammation in adipose tissues. Increased browning of white adipose tissue and energy expenditure were also seen with imatinib

"Taken together, Gleevec exhibits greater beneficial effects on both glucose/lipid metabolism and energy homeostasis by blocking PPAR γ phosphorylation," the authors write. "These data illustrate that Gleevec could be a novel therapeutic agent for use in insulin resistance and type 2 diabetes."

One author was employed by Hyundai Pharm Co.

More information: <u>Abstract</u>

Full Text (subscription or payment may be required)

Copyright © 2016 <u>HealthDay</u>. All rights reserved.



Citation: PPAR-gamma antagonist imatinib improves insulin sensitivity (2016, January 13) retrieved 4 May 2024 from https://medicalxpress.com/news/2016-01-ppar-gamma-antagonist-imatinib-insulin-sensitivity.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.